A5061703808- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Vasculitis and related conditions
- Urticaria and Related Conditions
- Mesenchymal stem cell research
- Otitis Media and Relapsing Polychondritis
- Systemic Sclerosis and Related Diseases
- Peripheral Neuropathies and Disorders
- Inflammatory Myopathies and Dermatomyositis
- Liver Diseases and Immunity
- IgG4-Related and Inflammatory Diseases
- T-cell and B-cell Immunology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Renal Diseases and Glomerulopathies
- HER2/EGFR in Cancer Research
- Ocular Diseases and Behçet’s Syndrome
- Bone and Joint Diseases
- Cytokine Signaling Pathways and Interactions
- Viral Infections and Immunology Research
- Peptidase Inhibition and Analysis
- Musculoskeletal synovial abnormalities and treatments
University of Occupational and Environmental Health Japan
2016-2025
Kobe University
2014
Oita University
2014
United Arab Emirates University
2011
Saitama Medical University
2011
We present a case report of 23-year-old Pakistani woman who had second trimester spontaneous miscarriage while visiting her family in the Kingdom Saudi Arabia. A dilatation and curettage (D&C) was done after miscarriage. She developed sepsis acute respiratory distress syndrome, requiring intensive care unit admission few days D&C. An exploratory laparotomy she found to have pelvic abscess. Despite adequate broad spectrum antimicrobial cover, continued drain copious amount serous...
Abstract Objective Mesenchymal stem cells (MSCs) are considered to be a novel tool for the treatment of rheumatoid arthritis (RA) because their multipotency differentiate into osteoblasts and chondrocytes, immunosuppressive effects, availability. The aim this study was assess mechanisms human MSC differentiation under inflammatory conditions. Methods Human MSCs were cultured in commercialized osteogenic induction medium with cytokines up 10 days. Osteoblast detected by alkaline phosphatase...
Objectives. To evaluate the effectiveness and safety of tocilizumab in RA patients clinical practice. Methods. We observed 232 consecutive who began three rheumatology centres Japan for 52 weeks. Clinical, radiographic functional status were evaluated. Results. Mean age was 59.1 years, mean duration disease 12.4 years average DAS using 28-joint count (DAS-28) 5.6. Although 62.8% had been treated previously with anti-TNF biologics, remission at Week achieved 43.7%, non-progression 26.4%....
Mesenchymal stem cells (MSCs) have been proposed to be a useful tool for treatment of rheumatoid arthritis (RA), not only because their multipotency but also immunosuppressive effect on lymphocytes, dendritic cells, and other proinflammatory cells. Since bone destruction caused by activated osteoclasts occurs in RA, we undertook the present study investigate MSCs osteoclast function differentiation order evaluate potential use RA therapy.Human peripheral blood mononuclear were cultured under...
Objective B cells play a pivotal role in the pathogenesis of autoimmune diseases. Although Syk functions as key molecule cell receptor signaling, pathologic rheumatoid arthritis (RA) remains unclear. The purpose this study was to assess relevance activation development RA and responsiveness patients treatment with biologics. Methods Healthy subjects (n = 36) moderate or severe disease activity 70) were studied. phosphorylation (pSyk) peripheral blood measured by flow cytometry, its...
This study aimed to clarify the usefulness of screening for malignancies using CT before initiation biologic and targeted synthetic DMARDs (b/tsDMARDs) in patients with active RA.We examined 2192 RA who underwent plain scans prior b/tsDMARDs. The sensitivity detecting malignancy was measured compared that regular (physical examination X-ray). We then evaluated clinical characteristics, prognosis treatment concomitant malignancies. Additionally, we determined incidence rate were initiated on...
The mechanisms of ectopic calcification in inflammatory diseases are poorly understood. We investigated the effects cytokines on human adipose tissue-derived mesenchymal stem cells (hADSCs).The were evaluated using hADSCs cultured osteoblast induction medium. mRNA expression was measured by real-time PCR and protein levels western blotting. Cell mineralization Alizarin Red S staining.In hADSCs, administration IL-6/soluble IL-6 receptor (sIL-6R), TNF or IL-1β accelerated through enhanced an...
Objective. Rituximab has recently emerged as a novel treatment strategy for systemic lupus erythematosus (SLE). We investigated longitudinally the differentiation and phenotypic changes of peripheral B cells T in patients with SLE after rituximab treatment. Methods. Phenotypic on 10 treated were analyzed before, 28 days after, 2 years treatment, at relapse. Results. rapidly depleted naive memory from blood. In prolonged remission, remained while recovered within 3–9 months, expression levels...
Objective Mesenchymal stem cells (MSCs) can differentiate into of mesenchymal lineages, such as osteoblasts and chondrocytes. Here we investigated the effects IL-17, a key cytokine in chronic inflammation, on chondrogenic differentiation human MSCs. Methods Human bone marrow MSCs were pellet cultured induction medium containing TGF-β3. Chondrogenic was detected by cartilage matrix accumulation marker gene expression. Results Over-expression genes noted cultures, but inhibited IL-17...
<h3>Objective</h3> To compare the clinical outcomes at 1 year after treatment with either abatacept or tocilizumab in patients rheumatoid arthritis routine practice. <h3>Methods</h3> overcome potential bias allocation to tocilizumab, a propensity score based on multiple baseline characteristics variables was calculated and 102 of 194 treated 273 were statistically extracted. Clinical assessed. <h3>Results</h3> The comparable. At week 52, 72%/69% (abatacept/tocilizumab) still receiving...
Objectives. To assess the effects of tofacitinib on T lymphocytes in RA patients with a special focus efficacy and infectious adverse events (iAEs). Methods. Forty-four participated 12-month phase II/III randomized clinical trials an open-label extension trial. Peripheral lymphocyte subsets vitro CD4+ proliferation were measured 23 44 at baseline end Results. [35 females, age 54.3 years, disease duration 84.3 months, simplified activity index (SDAI) 36.5, CRP 24.9 mg/l, ESR 53 mm/h, MMP-3...
Abstract Background Mepolizumab (MPZ), an anti-interleukin-5 antibody, is effective for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). However, its effectiveness has not been adequately evaluated in real-world clinical practice. In this study, we assessed and safety MPZ (300 mg) relapsing/refractory EGPA resistant to corticosteroids (CS) 1 year settings. Methods We administered 16 patients CS (Post-MPZ). also retrospectively collected data from same 12 months before...
Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid arthritis (RA) patients clinical practice have not been sufficiently investigated. Purpose this study is to investigate whether activity score 28 (DAS28)- erythrocyte sedimentation rate (ESR) remission was preserved discontinuation ADA with RA.This an observational but a randomized controlled study. Among 197 RA who initiated combination concomitant MTX, 69 (35%) acquired DAS28 < 2.6 for at least...
Abstract Objective To determine the safety and efficacy of anifrolumab in patients with systemic lupus erythematosus (SLE) classified based on Lupus Low Disease Activity State (LLDAS) real-world clinical practice. Methods This retrospective observational study involved SLE who started therapy. The primary end point was retention rate over 26 weeks after initiating therapy; 45 followed up for 12 or longer were analysed following groups to week treatment initiation: (i) non-LLDAS achievement...
Abstract Objectives : Mepolizumab (MPZ), an anti-interleukin-5 antibody, is effective for treating eosinophilic granulomatosis with polyangiitis (EGPA). However, its effectiveness has not been adequately evaluated in real-world clinical practice. In this study, we assessed the and safety of 300 mg MPZ relapsing/refractory EGPA resistant to corticosteroids (CS) 1 year settings. Methods We administered (300 mg) 16 patients CS (with-MPZ). also retrospectively collected data from same 12 months...
Mesenchymal stem cells (MSC) have been used recently for the treatment of autoimmune diseases in murine animal models due to immunoregulatory capacity. Current utilization MSC requires certain quantity with multiple courses administration, leading limitation clinical usage. Here we efficiently treated collagen-induced arthritis rats a single local implantation reduced number (2∼20% previous studies) nano-fiber poly-lactic-co-glycolic acid (nano-fiber) scaffold. seeded on scaffold suppressed...
An 81-year-old man was admitted with bilateral pleural effusion. A clinical examination showed lymphocytic pleura effusion and elevated serum IgG4 levels, so that IgG4-related disease suggested, whereas tuberculous pleurisy suspected because of high adenosine deaminase (ADA) levels in the surgical biopsy revealed there were large numbers IgG4-positive cells IgG4/IgG positive cell ratio exceeded 40% several sites. Accordingly, we diagnosed pleuritis treated patient glucocorticoid therapy. The...
Objectives. To examine the effectiveness of tocilizumab (TCZ) in preventing joint destruction patients with inadequate response to tumor necrosis factor inhibitors (TNF-IR) by assessing X-rays. Methods. RA were extracted from Retrospective actemra investigation for optimal needs (REACTION) study. Parameters and components disease activity evaluated during anti-TNF treatment TCZ treatment. X-ray images hands feet at beginning this study (Pre), start point (Baseline) after (Post) collected...
Abstract Aim The effectiveness and safety of hydroxychloroquine ( HCQ ) have not been fully validated in Japanese patients with systemic lupus erythematosus SLE the clinical setting. This study evaluated short‐term continuation rate therapy setting for 12 months. Methods primary endpoint was defined as up to months after introduction 122 . secondary endpoints included changes Disease Activity Index SLEDAI British Isles Lupus Assessment Group BILAG index, effect on concomitant corticosteroid...
Objective: Evaluate the association between multi-biomarker disease activity (MBDA) score and radiographic progression in patients with rheumatoid arthritis (RA) treated tumor necrosis factor (TNF)-α inhibitors. Methods: Change (Δ) modified total Sharp (mTSS) over 52 weeks scores were examined retrospectively by Spearman's rank correlation coefficient (N = 83) RA initiating TNF-inhibitor treatment. Relative risk (RR) of ΔmTSS >0.5 for low MBDA 28-joint count (DAS28) categories associations...
Tumor necrosis factor (TNF) inhibitors (TNF-i) are effective in the treatment of entero-Behcet's disease (BD). However, there is no objective tool for assessment activity entero-BD; therefore, it not easy to evaluate effectiveness clinical setting. In addition, because corticosteroid (CS) considered standard therapy, TNF-i without CS has been well examined. this retrospective study, and with or therapy were investigated compared.This study included 71 patients entero-BD who followed up 1...
Abstract Aim In this retrospective study, the effect of hydroxychloroquine (HCQ) added to maintenance therapy according standard care (SoC) was evaluated for 1 year in 101 patients with systemic lupus erythematosus (SLE). Methods The primary endpoint SLE Disease Activity Index (SLEDAI). secondary endpoints were British Isles Lupus Assessment Group index, serum complement activity (CH50) levels, anti‐double‐stranded DNA (dsDNA) antibody titer, concomitant corticosteroid (CS) dose, and...
Objectives Our objectives in this study were to determine the inhibitory effects of abatacept on joint damage and its clinical efficacy safety patients with rheumatoid arthritis (RA). Methods Fifty Japanese RA treated for 24 weeks routine practice. Results At week 24, 20 % achieved remission [Simplified Disease Activity Index (SDAI) ≤3.3], whereas 50 or had a low disease activity. Structural [progression modified total Sharp score (ΔmTSS) ≤0.5] was 76 patients. The ΔmTSS decreased...